TEST METHOD VALIDATION IN MOLECULAR DIAGNOSTICS IN RUSSIA

1. INTRODUCTION

Test method validation in molecular diagnostics refers to the systematic process of establishing and documenting that a diagnostic testing procedure is suitable for its intended medical purpose. Molecular diagnostic methods include polymerase chain reaction (PCR), real-time PCR, nucleic acid sequencing, genetic variant detection, molecular oncology testing, and other laboratory techniques used to identify genetic or molecular abnormalities.

In Russia, validation of molecular diagnostic methods is governed by pharmaceutical and medical-device legislation, healthcare quality requirements, laboratory accreditation standards, technical regulations, and applicable Eurasian Economic Union (EAEU) requirements.

The principal objective is to ensure that diagnostic tests produce accurate, reproducible, reliable, and clinically meaningful results. Improper validation can result in false-positive or false-negative diagnoses, inappropriate treatment decisions, patient injury, and professional or institutional liability.

2. LEGAL AND REGULATORY FRAMEWORK IN RUSSIA

A. FEDERAL LAW NO. 323-FZ OF 21 NOVEMBER 2011 ON THE FUNDAMENTALS OF HEALTH PROTECTION OF CITIZENS

This legislation establishes the general framework for medical services, patient safety, medical documentation, and healthcare professional responsibilities.

Its relevance includes:

Quality and safety of medical services.

Patient rights and informed consent.

Medical confidentiality.

Healthcare professional accountability.

Compliance with applicable medical standards.

Molecular diagnostic laboratories must ensure that testing procedures are appropriately organised and that diagnostic results are used responsibly in clinical decision-making.

B. FEDERAL LAW NO. 102-FZ OF 26 JUNE 2008 ON ENSURING THE UNIFORMITY OF MEASUREMENTS

This legislation establishes requirements concerning measurement accuracy, traceability, and reliability.

It is relevant to molecular diagnostic laboratories because analytical measurements, calibration procedures, and measurement equipment must satisfy applicable metrological requirements.

C. FEDERAL LAW NO. 184-FZ OF 27 DECEMBER 2002 ON TECHNICAL REGULATION

This legislation establishes general principles governing technical regulation, conformity assessment, and applicable technical requirements.

It may be relevant to diagnostic equipment and regulated medical-device products.

D. FEDERAL LAW NO. 61-FZ OF 12 APRIL 2010 ON CIRCULATION OF MEDICINES

This legislation regulates medicinal products rather than independently establishing a complete framework for laboratory test validation.

It becomes relevant when molecular diagnostic methods are used in clinical investigations or pharmaceutical development.

E. FEDERAL LAW NO. 412-FZ OF 28 DECEMBER 2013 ON ACCREDITATION IN THE NATIONAL ACCREDITATION SYSTEM

This legislation establishes the national accreditation framework.

Laboratories seeking accreditation must satisfy applicable competence, impartiality, quality-management, and technical requirements.

GOST ISO/IEC 17025 and GOST ISO 15189 are important technical standards in laboratory quality and competence assessment, subject to their applicable scope and accreditation requirements.

3. VALIDATION REQUIREMENTS FOR MOLECULAR DIAGNOSTIC TESTS

Method validation should demonstrate that a diagnostic procedure is fit for its intended purpose.

The principal validation characteristics include:

Analytical accuracy: Whether the method produces results consistent with appropriate reference materials or established comparison methods.

Analytical sensitivity: The ability to detect the target analyte at relevant concentrations.

Analytical specificity: The ability to distinguish the intended molecular target from unrelated substances or sequences.

Precision and reproducibility: The consistency of results under specified testing conditions.

Limit of detection: The lowest analyte concentration that can be reliably detected under defined conditions.

Robustness: The ability of the method to remain reliable despite reasonable variations in testing conditions.

Interference assessment: Evaluation of substances or sample characteristics that may affect test performance.

Reference interval or decision threshold verification: Establishing appropriate interpretation criteria for the intended clinical application.

Validation requirements should be proportionate to the test's clinical purpose, technology, and potential consequences of an incorrect result.

4. REGULATION OF PCR AND GENETIC TESTING METHODS

PCR-based diagnostic methods are widely used for infectious disease detection, hereditary disease diagnosis, and oncology testing.

Russian laboratories should ensure that testing methods are supported by appropriate analytical evidence and quality-management documentation.

Important areas include:

Verification of equipment performance.

Qualification of laboratory personnel.

Documentation of analytical performance.

Appropriate reference materials.

Prevention of sample contamination.

Traceability of test results.

Control of measurement uncertainty where relevant.

Documented review and approval of testing procedures.

For next-generation sequencing and genetic variant analysis, additional considerations include bioinformatics performance, variant interpretation, data integrity, and the limitations of the testing platform.

5. MEDICAL-DEVICE REGULATION AND DIAGNOSTIC KIT APPROVAL

Molecular diagnostic kits and instruments may fall within medical-device regulatory frameworks.

Two important regulatory systems must be distinguished:

A. RUSSIAN NATIONAL REGISTRATION SYSTEM

Russian medical-device registration is governed principally by Federal Law No. 323-FZ and Government Resolution No. 1416 of 27 December 2012, subject to applicable amendments and transitional provisions.

Roszdravnadzor supervises relevant medical-device registration and circulation requirements.

B. EURASIAN ECONOMIC UNION SYSTEM

EAEU medical-device regulatory requirements are established through the applicable EAEU agreements and decisions, including Decision No. 46 of 12 February 2016 concerning medical-device registration and examination.

Diagnostic manufacturers must determine which regulatory pathway applies to their product.

Analytical validation evidence, clinical performance evidence, manufacturing quality documentation, and conformity requirements may be required depending on the device classification and intended use.

6. DOCUMENTATION AND QUALITY MANAGEMENT REQUIREMENTS

A molecular diagnostic laboratory should maintain a documented validation and quality-management system.

Essential records include:

Test method description and intended clinical application.

Validation protocol and acceptance criteria.

Analytical performance evaluation.

Reference material documentation.

Equipment calibration and maintenance records.

Personnel qualification records.

Internal quality-control documentation.

External quality-assessment participation, where applicable.

Corrective and preventive action records.

Final validation approval and periodic review documentation.

Laboratories should also establish procedures for investigating unexpected results, reporting testing errors, and withdrawing or correcting inaccurate reports when necessary.

7. PATIENT RIGHTS AND PROFESSIONAL LIABILITY

Federal Law No. 323-FZ provides important protections concerning the quality and safety of medical care.

A patient may have legal grounds to pursue a claim where an incorrectly validated or improperly performed molecular diagnostic test causes harm.

Potential liability may arise from:

Negligent laboratory testing.

Failure to follow established procedures.

Inadequate quality control.

Incorrect interpretation of genetic results.

Failure to communicate clinically significant findings.

Use of unsuitable or defective diagnostic equipment.

Articles 1064 and 1095–1098 of the Russian Civil Code may become relevant to civil liability, depending on the circumstances and the legal relationship involved.

The existence of an inaccurate test result does not automatically establish liability. Negligence, causation, legally recognised harm, and other applicable requirements must be established.

8. IMPORTANT JUDICIAL DECISIONS

There is limited publicly established Russian case law specifically addressing molecular diagnostic test method validation. The following judgments provide analogous legal principles concerning medical responsibility, patient rights, and evidentiary assessment.

1. ARSKAYA v. UKRAINE (2013), EUROPEAN COURT OF HUMAN RIGHTS

The case concerned medical treatment, patient autonomy, and the state's positive obligations in healthcare.

Relevance: Provides comparative guidance on patient protection and the importance of responsible medical decision-making.

2. TROCELLIER v. FRANCE (2006), EUROPEAN COURT OF HUMAN RIGHTS

The case concerned medical treatment and the importance of providing patients with relevant information about medical risks.

Relevance: Offers an analogous principle supporting transparent communication of diagnostic limitations and clinically relevant uncertainty.

3. CALVELLI AND CIGLIO v. ITALY (2002), EUROPEAN COURT OF HUMAN RIGHTS

The Court examined the state's positive obligations concerning protection of life and the effectiveness of legal remedies in cases involving medical negligence.

Relevance: Provides comparative guidance concerning institutional accountability for serious medical failures.

4. VO v. FRANCE (2004), EUROPEAN COURT OF HUMAN RIGHTS

The Court considered the relationship between medical negligence, protection of life, and legal safeguards.

Relevance: Illustrates the importance of effective legal protection where medical errors have serious consequences.

5. L.C.B. v. UNITED KINGDOM (1998), EUROPEAN COURT OF HUMAN RIGHTS

The Court examined the state's positive obligations under the right to life in a medical and health-risk context.

Relevance: Provides an analogous human-rights perspective on the importance of addressing foreseeable health risks.

6. CALVETTI AND CIGLIO v. ITALY (2002), EUROPEAN COURT OF HUMAN RIGHTS

The same judgment is sometimes discussed in relation to medical accountability; it should not be treated as a separate authority from the decision identified above.

These European judgments are comparative authorities, not Russian domestic precedents. Their use in Russian legal analysis must account for Russia's withdrawal from the European Convention on Human Rights and the applicable temporal and jurisdictional limitations.

9. PRACTICAL COMPLIANCE AND ENFORCEMENT

Russian molecular diagnostic laboratories should implement the following safeguards:

Adopt written validation and verification policies.

Establish scientifically justified acceptance criteria.

Maintain appropriate laboratory accreditation.

Use suitable reference materials and quality controls.

Conduct periodic performance reassessments.

Maintain equipment and calibration records.

Ensure staff competency and training.

Protect confidential genetic and medical information.

Investigate diagnostic errors and document corrective actions.

Ensure that diagnostic claims correspond to the authorised intended use of regulated devices.

Regulatory authorities may take appropriate supervisory or enforcement action where laboratories or manufacturers violate applicable legal requirements.

10. CONCLUSION

Test method validation in molecular diagnostics in Russia is an essential component of healthcare quality, patient safety, and laboratory accountability. Federal Laws No. 323-FZ, 102-FZ, 184-FZ, and 412-FZ provide important statutory foundations, while GOST laboratory standards and EAEU medical-device requirements contribute to technical and quality-assurance obligations. Although there is no substantial body of Russian judicial precedent specifically addressing molecular diagnostic validation, comparative medical-liability decisions demonstrate the importance of reliable healthcare procedures, patient protection, and effective legal accountability. Ultimately, scientifically supported validation, proper documentation, competent personnel, and continuous quality monitoring are necessary to ensure trustworthy molecular diagnostic services.